Antiviral agents, a diverse class of pharmaceutical compounds, play a crucial role in combating viral infections by targeting specific stages of the viral life cycle. Nucleoside/nucleotide analogs, such as acyclovir and tenofovir, interfere with viral genome replication, inhibiting the synthesis of viral DNA or RNA. Protease inhibitors, like ritonavir and lopinavir, disrupt the maturation of viral proteins, particularly vital in managing retroviruses like HIV. Neuraminidase inhibitors, exemplified by oseltamivir, are instrumental in treating influenza by preventing the release of new virions from infected cells. The advent of RNA-based therapies, including RNA interference (RNAi) and CRISPR technologies, holds promise in providing precise tools to target and silence viral genetic material. Antiviral vaccines, exemplified by those against influenza and hepatitis, serve as preventive measures, stimulating the immune system to recognize and combat specific viral antigens. As the field advances, nanotechnology and immunotherapies emerge as innovative approaches, paving the way for more effective antiviral interventions.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain